Astellas Pharma is buying Audentes Therapeutics for about $3 billion in cash, that amounts to roughly 110% of the closing price for Audentes shares earlier this week. The move is designed to make genetic drugs a fifth primary focus for Astellas, joining existing business lines in regenerative, immuno-oncology, immunotherapy, and neuro-muscular medicine according to published reports. The acquisition marks the second biggest on record for Astellas after its 2010 purchase of OSI Pharmaceuticals for$3.8 billion. Astellas expects the deal, which is subject to regulatory approval including U.S. antitrust clearance, to close in the first quarter of 2020. Learn More